Klinička obilježja i preživljenje bolesnika s malignim mezoteliomom pleure – iskustvo jednog centra

Scientific paper - Original scientific paper

• Title (english): Clinical characteristics and survival of patients with malignant pleural mesothelioma: a single center study
• Author: Goran Glodić
• Author: Antun Koprivanac
• Author: Anton Mažuranić
• Author: Tomislav Dujmović
• Author: Ante Marušić
• Author: Sanja Pleština
• Author: Suzana Kukulj
• Author: Lela Bitar
• Author: Fran Seiwerth
• Author: Sven Seiwerth
• Author: Luka Brčić
• Author: Dinko Stančić Rokotov
• Author: Zoran Janevski
• Author: Željko Djaković
• Author: Feđa Džubur
• Author: Mateja Janković Makek
• Author: Gzim Redžepi
• Author: Miroslav Samaržija
• Author: Marko Jakopović
• Author's institution: University of Zagreb; School of Medicine; (Department of Internal Medicine)
• Author's institution: University of Zagreb; School of Medicine; (Department of Surgery)
• Author's institution: University of Zagreb; School of Medicine; (Department of Pathology)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Internal Medicine
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Pathology
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Surgery

Abstract (croatian)

Maligni pleuralni mezoteliom rijetka je i agresivna primarna novotvorina mezotelnih stanica pleure. Glavni rizični čimbenik je izloženost azbestu, najčešće uz latenciju od 30–50 godina. Unatoč terapiji medijan preživljenja je od 4 do 18 mjeseci, ovisno o izvoru. Cilj istraživanja bio je odrediti karakteristike bolesnika oboljelih od malignoga pleuralnog mezotelioma te ishode njihova liječenja na KBC Zagreb u razdoblju od 1999. do 2012. godine. Ispitane su karakteristike 101 bolesnika dijagnosticiranog i liječenog na KBC Zagreb u razdoblju od rujna 1999. do rujna 2012. Analizirali smo ukupno preživljenje (OS), preživljenje bez progresije bolesti (PFS) te preživljenje ovisno o histološkom podtipu tumora, dobi, kliničkom stadiju, pleurodezi talkom i modalitetu liječenja.
Koristili smo Kaplan-Meierovu metodu za izradu krivulje preživljenja. 89 bolesnika bilo je muškog, 12 ženskog spola, a medijan dobi 62 godine. Prema TNM klasifikaciji stadij IV je utvrđen kod 69,3%, stadij III kod 26,73%, te stadij II kod samo 3,96% bolesnika. 73,26% bolesnika imalo je epiteloidni, 4,95% sarkomatoidni, 1% mješoviti te 20,79% NOS (nespecifirani) histološki podtip bolesti. Kirurški je liječeno 14,85% bolesnika, kemoterapijom 55,44%, dok je radioterapija primijenjena kod 9,9% bolesnika. Medijan OS iznosi 11 mjeseci, dok je PFS 10 mjeseci.
Prema histološkom podtipu medijan OS iznosio je 11 mjeseci za epiteloidni, 12,5 za NOS te 5,5 za sarkomatoidni, a prema kliničkom stadiju 7 mjeseci za stadij II, 17,5 mjeseci za stadij III te 11 mjeseci za stadij IV. Medijan OS bio je dulji u skupini bolesnika mlađoj od 65 godina (12 naspram 8,5 mjeseci, p=0.28), skupini sa učinjenom pleurodezom (13 naspram 7,5 mjeseci, p=0.06) te u skupini liječenoj kemoterapijom (12,5 naspram 7,5 mjeseci, p=0.10). Očekivano preživljenje bolesnika oboljelih od malignoga pleuralnog mezotelioma u Republici Hrvatskoj
u skladu je s podatcima iz literature. Ispitane metode liječenja relativno skromno utječu na preživljenje bolesnika.

Abstract (english)

Malignant pleural mesothelioma (MPM) is an aggressive tumor that develops from the mesothelial cells lining the pleural cavity. The most relevant risk factor is asbestos exposure. Despite therapy the median
survival is poor ranging from four to 18 months. The aims and objectives of this study were to assess the clinical characteristics and survival of patients with MPM treated at UHC Zagreb. This study included 101 patients diagnosed and treated for MPM at UHC Zagreb from September 1999 to September 2012. We analyzed the overall survival (OS), progression free survival (PFS) and OS depending on histological subtype, clinical stage, age, treatment method and pleurodesis performed using the Kaplan-Meier method. Eighty-nine patients were male and 12 female with the median age of 62 years. Using the TNM staging system, 69.3% were stage IV, 26.73% were stage III and 3.96% were stage II. 73.26% of MPM were epitheloid, 4.95% sarcomatous and 20.79% were NOS (non otherwise specified) histological subtype. 14.85% of patients had surgery, 55.44% of patients received chemotherapy and 9.9% radiotherapy. Median OS was 11 months and PFS was ten months. OS by histological subtype was 11 months for epitheloid, 12.5 months for NOS and 5.5 months for sarcomatous MPM. OS by TNM stage was seven months for stage II, 17.5 months for stage III and 11 months for stage IV disease. Median OS was longer for patients younger than 65 (12 vs. 8.5 months, p=0.28), patients treated with pleurodesis (13 vs. 7.5 months, p=0.06) and patients who received chemotherapy (12.5 vs. 7.5 months, p=0.10). The overall survival and prognosis of patients with malignant pleural mesothelioma in Croatia is poor in accordance with the literature. The studied treatment methods offer only a modest survival benefit to our patients.

• Keywords (croatian): MEZOTELIOM – dijagnoza, liječenje, patologija; PLEURALNI TUMORI – dijagnoza,liječenje, patologija; TUMORSKI STADIJ; AZBEST –toksičnost; MULTIMODALNO LIJEČENJE; TORAKALNI KIRURŠKI ZAHVATI; PROTUTUMORSKI KEMOTERAPIJSKI PROTOKOLI – terapijska uporaba; RADIOTERAPIJA; PLEURODEZA; TALK; ANALIZA PREŽIVLJENJA; KAPLAN-MEIEROVA ANALIZA
• Keywords (english): MESOTHELIOMA – diagnosis, pathology, therapy; PLEURAL NEOPLASMS – diagnosis, pathology, therapy; NEOPLASM STAGING; ASBESTOS – toxicity; COMBINED MODALITY THERAPY; THORACIC SURGICAL PROCEDURES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS – therapeutic use; RADIOTHERAPY; PLEURODESIS; TALC; SURVIVAL ANALYSIS; KAPLAN-MEIER ESTIMATE
• Language: croatian
• Language: english
• Publication type: Scientific paper - Original scientific paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: Liječnički vjesnik
• Numbering: vol. 142, no. 9-10, pp. 306-314
• p-ISSN: 0024-3477
• e-ISSN: 1849-2177
• DOI: https://doi.org/10.26800/LV-142-9-10-47
• URN:NBN: urn:nbn:hr:105:577592
• Publication: 2020
• Document URL: https://hrcak.srce.hr/245806
• Type of resource: Text
• Access conditions: Open access
• Created on: 2020-12-04 13:06:42